Core Viewpoint - Mandi International has submitted an IPO application to the Hong Kong Stock Exchange, aiming for an independent listing, following the announcement of its spin-off from 3SBio, which will no longer retain any equity in Mandi International [1][3]. Company Overview - Mandi International focuses on developing comprehensive and long-term solutions for skin health and weight management, launching its first 5% minoxidil product in China in 2001, thus entering the hair loss treatment market early [3]. - The Mandi series, which includes products like Mandi 5% minoxidil solution and foam, constitutes a significant portion of the company's revenue, accounting for 91.7% to 92.3% of total product sales from 2022 to 2024 [3][4]. Financial Performance - Mandi International's revenue from 2022 to 2024 is projected to be CNY 9.82 billion, CNY 12.28 billion, and CNY 14.55 billion, with year-on-year growth rates of 25.05% and 18.49% for 2023 and 2024, respectively [4]. - The net profit for the same period is expected to be CNY 2.02 billion, CNY 3.41 billion, and CNY 3.9 billion, with significant growth rates of 68.81% and 14.37% in 2023 and 2024 [4]. Market Dynamics - The hair loss treatment market in China is projected to grow to CNY 21 billion by 2024, with over 339 million people affected by hair loss, more than 60% of whom are under 35 years old [3][4]. - The market for hair loss products has become highly competitive, with various companies, including traditional hair care brands and new entrants from the beauty and pharmaceutical sectors, vying for market share [5][6]. Future Plans - Mandi International plans to use the net proceeds from the IPO for enhancing R&D capabilities, digital operations, brand building, and working capital [4]. - The company aims to solidify its leading position in the hair health sector and accelerate the launch of new business segments [4].